Journal of Clinical Gastroenterology and Hepatology Open Access

  • ISSN: 2575-7733
  • Journal h-index: 5
  • Journal CiteScore: 0.63
  • Journal Impact Factor: 0.41
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

12 Weeks Hepatitis C Virus Antiviral Regimen is a Better Choice than 24 Weeks Regimen in North Region of Pakistan

Annual Summit on Hepatology and Pancreatic Diseases
November 12-13, 2018 Paris, France

Tanveer Ahmed, Mashhood Ali, Faisal Rasheed

Shaheed Zulfiqar Ali Bhutto Medical University, Pakistan Pakistan Institute of Nuclear Science and Technology, Pakistan

Posters & Accepted Abstracts: J Clin Gastroenterol Hepatol

Abstract:

Background: Hepatitis C Virus (HCV) infection is an important health issue and leading cause of chronic liver disease in developing countries including Pakistan. Therefore, the current study was aimed to assess the treatment responses of available antiviral regimens. Methods: A total of 144 chronic HCV positive patients by real time PCR were enrolled from Department of Gastroenterology, Pakistan Institute of Medical Sciences (PIMS), Islamabad (North Region), Pakistan. Treatment responses among chronic HCV positive patients were observed for antiviral regimens. These antiviral regimens were Sofosbuvir + Ribavirin (24 weeks) and Sofosbuvir + Daclatasvir (12 Weeks). Sofosbuvir (400 mg), (Sovaldi , Gilead Sciences, USA) and Daclatasvir (60 mg ), (MyDekla, Mylan , USA/Dacklinza, Bristo Myers Squibb, USA) were prescribed to take orally once a day. In addition, Ribavirin (Xolox, Ferozsons, Pakistan), (400 mg or 600 mg ) had been advised to take orally twice daily on the basis of weight of patients. The end of treatment response (ETR) after completion of treatment and sustained virological response (SVR) after 12 weeks of cessation of treatment were assessed by the detection of HCV RNA in sera of treated patients. Results: The high ETR and SVR were achieved with Sofosbuvir + Daclatasvir (12 weeks), (92.26%, 71/73) when compared with Sofosbuvir + Ribavirin (24 weeks), (84.50%, 60/71) among chronic HCV positive patients. Conclusions: In conclusion, the 12 weeks HCV antiviral eradication regimen i.e., Sofosbuvir + Daclatasvir was more effective, economic and a better choice than 24 weeks regimen ‘Sofosbuvir + Ribavirin’ in our region.

Biography :

E-mail:

ahmedtanveer17@yahoo.com